128 related articles for article (PubMed ID: 22859265)
1. Atopaxar. A novel player in antiplatelet therapy?
Wurster T; May AE
Hamostaseologie; 2012; 32(3):228-33. PubMed ID: 22859265
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial.
O'Donoghue ML; Bhatt DL; Wiviott SD; Goodman SG; Fitzgerald DJ; Angiolillo DJ; Goto S; Montalescot G; Zeymer U; Aylward PE; Guetta V; Dudek D; Ziecina R; Contant CF; Flather MD;
Circulation; 2011 May; 123(17):1843-53. PubMed ID: 21502577
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial.
Wiviott SD; Flather MD; O'Donoghue ML; Goto S; Fitzgerald DJ; Cura F; Aylward P; Guetta V; Dudek D; Contant CF; Angiolillo DJ; Bhatt DL;
Circulation; 2011 May; 123(17):1854-63. PubMed ID: 21502571
[TBL] [Abstract][Full Text] [Related]
4. Atopaxar.
Wurster T; May AE
Hamostaseologie; 2012; 32(3):228-233. PubMed ID: 29589364
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of action and clinical development of platelet thrombin receptor antagonists.
Ueno M; Ferreiro JL; Angiolillo DJ
Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1191-200. PubMed ID: 20670195
[TBL] [Abstract][Full Text] [Related]
6. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
Duerschmied D; Bode C
Hamostaseologie; 2012; 32(3):221-7. PubMed ID: 22777302
[TBL] [Abstract][Full Text] [Related]
7. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
Packard KA; Campbell JA; Knezevich JT; Davis EM
Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
[TBL] [Abstract][Full Text] [Related]
8. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.
Kogushi M; Matsuoka T; Kawata T; Kuramochi H; Kawaguchi S; Murakami K; Hiyoshi H; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I
Eur J Pharmacol; 2011 Apr; 657(1-3):131-7. PubMed ID: 21300059
[TBL] [Abstract][Full Text] [Related]
9. Protease-activated receptor-1 antagonists: focus on SCH 530348.
Sugunaraj JP; Mehta V; Kalra A; Sukhija R; Palaniswamy C
Am J Ther; 2012 Nov; 19(6):465-9. PubMed ID: 21248619
[TBL] [Abstract][Full Text] [Related]
10. Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.
Macaulay TE; Allen C; Ziada KM
Expert Opin Pharmacother; 2010 Apr; 11(6):1015-22. PubMed ID: 20307225
[TBL] [Abstract][Full Text] [Related]
11. Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
Rollini F; Tello-Montoliu A; Angiolillo DJ
Future Cardiol; 2012 Jul; 8(4):503-11. PubMed ID: 22871190
[TBL] [Abstract][Full Text] [Related]
12. Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.
Hildemann SK; Bode C
Hamostaseologie; 2009 Nov; 29(4):349-55. PubMed ID: 19882073
[TBL] [Abstract][Full Text] [Related]
13. Protease-activated receptor-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with acute coronary syndrome.
Leonardi S; Tricoci P; Becker RC
Adv Cardiol; 2012; 47():87-99. PubMed ID: 22906905
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.
Goto S; Ogawa H; Takeuchi M; Flather MD; Bhatt DL;
Eur Heart J; 2010 Nov; 31(21):2601-13. PubMed ID: 20805115
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of the thrombin receptor antagonist E5555 (atopaxar) attenuates intimal thickening following balloon injury in rats.
Kogushi M; Matsuoka T; Kuramochi H; Murakami K; Kawata T; Kimura A; Chiba K; Musha T; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I
Eur J Pharmacol; 2011 Sep; 666(1-3):158-64. PubMed ID: 21635884
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.
Tomasello SD; Angiolillo DJ; Goto S
Expert Opin Investig Drugs; 2010 Dec; 19(12):1557-67. PubMed ID: 20979570
[TBL] [Abstract][Full Text] [Related]
17. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives.
Moschonas IC; Goudevenos JA; Tselepis AD
Int J Cardiol; 2015 Apr; 185():9-18. PubMed ID: 25777282
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet therapy: thrombin receptor antagonists.
Tello-Montoliu A; Tomasello SD; Ueno M; Angiolillo DJ
Br J Clin Pharmacol; 2011 Oct; 72(4):658-71. PubMed ID: 21906120
[TBL] [Abstract][Full Text] [Related]
19. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis.
Oestreich J
Curr Opin Investig Drugs; 2009 Sep; 10(9):988-96. PubMed ID: 19705342
[TBL] [Abstract][Full Text] [Related]
20. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
White HD
Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
